AGP Executive Report
Last update: 3 minutes agoMedical Cannabis Research: India’s CSIR-IIIM is advancing a project to develop cannabis-based medicines for pain, neuropathies, cancer and epilepsy, with officials describing it as a step toward export-quality treatments. Industry Under Pressure: UK medicinal cannabis supplier Grow Group secured £2 million in new equity and a £10 million debt-for-equity swap, and named Clare Holliday and Pierre van Weperen as co-CEOs. Meanwhile, a federal hemp measure due Dec. 11 could remove many hemp-derived products from the U.S. market, threatening CBD-focused growers; Illinois’ ban on intoxicating hemp products is due to begin Thursday. Health Watch: Recent studies linked cannabis use to higher mortality among people with alcohol-associated hepatitis and to increased stroke and cardiovascular risks. The findings show associations, not proof that cannabis caused the outcomes.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.